Free Trial

Atara Biotherapeutics (ATRA) Competitors

Atara Biotherapeutics logo
$9.48 +0.25 (+2.71%)
Closing price 04:00 PM Eastern
Extended Trading
$9.46 -0.02 (-0.21%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATRA vs. ORIC, CTMX, DRUG, SOPH, FDMT, YMAB, ENGN, EPRX, GNFT, and OGI

Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), SOPHiA GENETICS (SOPH), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), enGene (ENGN), Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), and Organigram Global (OGI). These companies are all part of the "pharmaceutical products" industry.

Atara Biotherapeutics vs. Its Competitors

Atara Biotherapeutics (NASDAQ:ATRA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 4.0% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 6.8% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Atara Biotherapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Oric Pharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.

Atara Biotherapeutics presently has a consensus price target of $17.75, indicating a potential upside of 87.24%. Oric Pharmaceuticals has a consensus price target of $18.57, indicating a potential upside of 62.20%. Given Atara Biotherapeutics' higher probable upside, equities research analysts clearly believe Atara Biotherapeutics is more favorable than Oric Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atara Biotherapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57
Oric Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 1 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.26 beat Atara Biotherapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Atara Biotherapeutics Neutral
Oric Pharmaceuticals Neutral

Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -7.83%. Atara Biotherapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Atara Biotherapeutics-7.83% N/A -14.51%
Oric Pharmaceuticals N/A -51.14%-46.29%

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara Biotherapeutics$128.94M0.44-$85.40M-$3.72-2.55
Oric PharmaceuticalsN/AN/A-$127.85M-$1.87-6.12

Summary

Oric Pharmaceuticals beats Atara Biotherapeutics on 9 of the 16 factors compared between the two stocks.

Get Atara Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATRA vs. The Competition

MetricAtara BiotherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$55.02M$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E Ratio-2.5521.1127.1820.14
Price / Sales0.44292.18440.78137.14
Price / CashN/A42.7337.5058.41
Price / Book-0.567.748.085.60
Net Income-$85.40M-$54.96M$3.16B$248.43M
7 Day Performance18.35%6.04%3.77%5.15%
1 Month Performance3.95%4.47%3.90%7.62%
1 Year Performance5.10%6.12%34.22%21.56%

Atara Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATRA
Atara Biotherapeutics
4.1164 of 5 stars
$9.48
+2.7%
$17.75
+87.2%
+14.0%$55.02M$128.94M-2.55330
ORIC
Oric Pharmaceuticals
4.642 of 5 stars
$10.65
-1.4%
$19.17
+80.0%
+16.7%$920.42MN/A0.0080Analyst Forecast
CTMX
CytomX Therapeutics
4.2022 of 5 stars
$2.37
-5.2%
$5.33
+125.0%
+84.4%$201.55M$138.10M5.21170News Coverage
DRUG
Bright Minds Biosciences
2.4871 of 5 stars
$27.33
-3.7%
$83.25
+204.6%
+2,493.2%$199.84MN/A-75.91N/A
SOPH
SOPHiA GENETICS
2.3903 of 5 stars
$3.25
+8.7%
$7.00
+115.4%
-18.9%$199.39M$65.17M0.00520Positive News
High Trading Volume
FDMT
4D Molecular Therapeutics
2.1296 of 5 stars
$3.95
-6.8%
$29.56
+648.2%
-80.5%$196.42M$40K0.00120
YMAB
Y-mAbs Therapeutics
3.2974 of 5 stars
$4.22
-1.9%
$15.60
+269.7%
-60.6%$194.72M$87.68M-6.59150
ENGN
enGene
2.8149 of 5 stars
$3.81
+0.3%
$23.29
+511.2%
-57.5%$194.20MN/A0.0031Trending News
EPRX
Eupraxia Pharmaceuticals
2.1324 of 5 stars
$5.54
+2.8%
$11.00
+98.6%
+106.0%$193.81MN/A0.0029Gap Up
GNFT
GENFIT
2.0798 of 5 stars
$3.69
-4.8%
$13.00
+252.7%
-12.2%$193.49M$76.77M0.00120News Coverage
Positive News
OGI
Organigram Global
0.9872 of 5 stars
$1.39
-2.8%
N/A-8.3%$191.53M$117.47M0.00860News Coverage

Related Companies and Tools


This page (NASDAQ:ATRA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners